The stock market rose on Thursday despite weaker-than-expected economic news and a mixed batch of earnings results. Specifically, gross domestic product grew at a 6.5% annual rate for the second quarter versus expectations for 8.5% growth.Additionally, jobless claims fell 24,000 to 400,000 versus forecasts for a print of 380,000. Despite the misses, the broader market and blue-chips broke out to...
Continue reading >>...
Continue reading >>The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...
Continue reading >>...
Continue reading >>The stock market was mostly higher on Friday following the June jobs report with another round of record highs for Tech and the broader market. Specifically, non-farm payrolls rose by 850,000, the sixth-straight monthly gain, versus forecasts for a print of 720,000. The unemployment rate, however, unexpectedly ticked up to 5.9% versus expectations for a dip to 5.6%. The small-caps failed to show...
Continue reading >>Oversold, OCGN is gaining momentum. According to Tip Ranks, “Ocugen has inked a deal with India-based Bharat Biotech for the US rights for the company’s vaccine COVAXIN. And Bharat has now reported positive second interim analysis results from the COVAXIN Phase 3 trials. The vaccine displayed an overall efficacy rate of 78%, with 100% success against severe cases of the disease. COVAXIN...
Continue reading >>